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ABSTRACT
Background Medication reviews for people 
transitioning from one healthcare setting to another 
potentially improve health outcomes, although evidence 
for outcome benefits varies. It is unclear when and 
why medication reviews performed by pharmacists in 
primary care for people who return from hospital to the 
community lead to beneficial outcomes.
Objective A realist synthesis was undertaken to develop 
a theory of what works, for whom, why and under which 
circumstances when pharmacists conduct medication reviews 
in primary care for people leaving hospital.
Methods The realist synthesis was performed in 
accordance with Realist And MEta- narrative Evidence 
Syntheses: Evolving Standards reporting standards. An initial 
programme theory informed a systematic literature search of 
databases (PubMed, Embase, Cumulative Index of Nursing 
and Allied Health Literature, International Pharmaceutical 
Abstracts, OpenGrey, Trove), augmented by agency and 
government sources of information. Documents were 
synthesised by exploring interactions between contexts, 
intervention, outcomes and causal mechanisms.
Results The synthesis identified 9 contexts in which 
10 mechanisms can be activated to influence outcomes 
of pharmacist medication reviews conducted in primary 
care postdischarge. For a medication review to take 
place these include trust patients have in healthcare 
professionals, their healthcare priorities postdischarge, 
capacity to participate, perceptions of benefit and 
effort, and awareness required by all involved. For 
the medication review process, mechanisms which 
issue an invitation to collaborate between healthcare 
professionals, enable pharmacists employing clinical skills 
and taking responsibility for medication review outcomes 
were linked to more positive outcomes for patients.
Conclusions Medication reviews after hospital discharge 
seem to work successfully when conducted according to 
patient preferences, programmes promote coordination and 
collaboration between healthcare professionals and establish 
trust, and pharmacists take responsibility for outcomes. 
Findings of this realist synthesis can inform postdischarge 
medication review service models.
INTRODUCTION
During the immediate period after 
leaving a hospital people experience 
heightened vulnerability and a risk of 
clinical deterioration.1 They may have 
been prescribed new medicines or 
changes applied to their regimen, which 
are intended to be temporary or perma-
nent. A lack of, or inadequate, commu-
nication between those involved in care 
can contribute to adverse outcomes from 
medicines when transferring from one 
care setting to another.2 3 These factors 
account for only some of the problems in 
the delivery of healthcare but contribute 
to the complexity which influences the 
benefits or harms people can experience 
from the prescription and use of medi-
cines.
In order to reduce the risk of adverse 
effects from medicines when people move 
between various healthcare settings, many 
governing bodies or quality agencies 
recommend strategies which ensure timely 
and accurate transfer of information and 
continuity of care.3 4 Pharmacists’ role in 
the care of people returning to primary 
care settings from hospital contributes 
to bridging information gaps, optimising 
outcomes and minimising harms.5 Their 
engagement at transitions of care ranges 
from performing medication reconcil-
iation to medication reviews (MR).3 6 7 
Both are supported by relatively robust 
evidence of avoidance of adverse events 
and cost reduction, mainly after patient 
admission into hospital, and are endorsed 
through healthcare standards.8–10
It is less clear what benefits can be 
derived for patients and health systems 
through medication reconciliation or MR 
when people transition from hospitals 
back to primary care. Although system-
atic reviews seem to show some benefit 
‘on average’, for example, a reduction in 
medication- related problems (MRP),11 12 
they have not identified a preferred, effec-
tive pharmacist- led intervention13 or 
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established a consensus for best practice.14 This may be 
related to variations of how MR are executed as inter-
ventions by individual practitioners or implemented 
as programmes within health services. Although most 
jurisdictions supporting medication reconciliation 
or MR for people moving from hospitals into the 
community provide procedural guidance on how to 
conduct a reconciliation or review, the reality of prac-
tice introduces variations.15 16 Results from individual 
studies vary significantly, some indicating that MR 
after hospital discharge may have benefit in reducing 
hospital readmissions or emergency hospital visits,17–20 
others casting doubt that tangible outcome benefits 
can be achieved21 or producing evidence of a negative 
effect.22 23
The majority of studies and subsequent system-
atic reviews focus on outcomes as a result of an MR, 
they provide limited detail as to how these outcomes 
have been achieved or explore the differing contexts 
that may have led to contradictory results. Adding 
to systematic reviews in the area,11–14 24 this realist 
synthesis was undertaken to clarify what works, for 
whom, why and under which circumstances in rela-
tion to MR performed face- to- face by pharmacists 
in primary care settings for people who return from 
hospital into the community. For the purpose of this 
review, the definition of MR by National Institute for 
Health and Care Excellence, UK, was adopted.3
Realist synthesis is a theory- driven approach to eval-
uating complex programmes, through an investigation 
of contexts, details of the intervention and identi-
fication of causal principles which explain why, for 
example, an MR programme works.25 26 It draws on 
academic and grey literature as well as policy docu-
ments, in this case relating to pharmacists providing 
some form of MR as an intervention in primary 
care for people who return from hospital into the 
community. The aim of the synthesis was to estab-
lish a programme theory of why, for whom, how and 
under which circumstances pharmacist- conducted MR 
succeed or fail to make differences to peoples’ health 
and healthcare utilisation after leaving hospital.
METHODS
Realist synthesis
Realist research explores the causal links between 
the context in which healthcare interventions or 
programmes take place, in this case MR, the mecha-
nisms which are triggered by the intervention in specific 
contexts and certain outcomes, which may be inter-
mediate or final. A realist approach to data synthesis 
endeavours to unpack the relationships between 
context, mechanisms and outcomes (CMO), providing 
an explanatory account and programme theory of why 
an intervention or programme achieves what it does.27 
As outlined previously, a realist approach to analysis 
will provide greater insight compared with existing 
systematic reviews examining when a pharmacist 
conducted MR after leaving hospital is likely to be 
successful.
Research questions
To support the generation of programme theory the 
following research questions were formulated using a 
Context- Intervention- Mechanism- Outcome (CIMO) 
framework.28
Context: what are the contexts in which a pharmacist- 
conducted MR may create an outcome benefit for 
patients after moving from hospital to primary care?
Intervention: what are the exact details of an MR 
performed by pharmacists in primary care for people 
who have been discharged from hospital as described 
in the literature?
Mechanism: what are the context- specific mech-
anisms which are likely to contribute to outcome 
benefits?
Outcome: what are the outcomes (related to C&M) 
achieved by pharmacist- conducted MR in primary 
care postdischarge?
The synthesis was registered on PROSPERO (2019 
CRD42019123825) and conducted by implementing 
practical guidance to realist research25 29 and applying 
Realist And MEta- narrative Evidence Syntheses: 
Evolving Standards (RAMESES) quality standards for 
publication of realist reviews.30
Development of initial programme theory
Scoping of the literature (based on prior knowledge by 
the research team and a PubMed search) facilitated the 
development of an initial programme theory around 
MR for people who move from hospitals to primary 
care. Documents which used the terms medication 
review, hospital discharge and community pharmacy 
were surveyed initially. At this point, literature was 
not analysed in depth nor data extracted, but was read 
for an overview and description of the medication 
review process to inform the generation of an initial 
programme theory. Documents were examined to 
identify any contexts and potential mechanisms which 
may explain when, why and how the MR process 
works for people who have left hospital. Regular 
discussions and comparisons of notes made on docu-
ments revealed the general assumptions underlying an 
MR, which are that pharmacists are skilled at iden-
tifying problems with medicines, including MRPs or 
prescriber, health system and patient- related issues and 
then identify and recommend appropriate solutions to 
these problems.4 As a result of identifying contexts and 
outcomes of interest, the process of medication review 
was separated into three steps to break down some of 
its inherent complexity. First, the MR had to be initi-
ated or ‘made’ to happen, then the actual MR itself 
performed by a pharmacist and the last step considers 
what occurs after the MR has been performed. The 
initial programme theory with contextual and inter-
ventional factors which were hypothesised to influence 
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these three steps are described in online supplemental 
appendix 1.
Data collection for realist synthesis
After designing and trialling the most appropriate search 
strategies in collaboration with a specialist librarian, a 
systematic search of PubMed, EMBASE, International 
Pharmaceutical Abstracts and Cumulative Index of 
Nursing and Allied Health Literature was performed 
in December 2018. Alerts for new articles which fit the 
search terms were set in PubMed, to facilitate timely 
additions of new publications during the synthesis, and 
the original search was repeated in February 2020. A start 
date was not set, as most relevant studies were conducted 
after the year 2000 but relevant discussion and policy 
documents possibly published earlier. Search strategies 
for each database are detailed in the supplementary 
materials (online supplemental appendix 2). OpenGrey 
and Trove databases were searched for grey literature as 
were the websites of pharmacy organisations and relevant 
government agencies in the UK, the USA, Canada and 
Australia. The focus of this realist synthesis was on MR 
performed by pharmacists working in community prac-
tice or primary care settings (eg, community pharmacy, 
general practice, community clinic), with no limitations 
to review locations. MR conducted in a hospital setting 
were excluded. Narrowing the scope of the review, 
searches did not include terms of ‘transition of care’ 
to minimise capturing MR performed by pharmacists 
working in hospital settings. Documents describing medi-
cation reconciliation were included if this was not the sole 
intervention. Programme evaluation reports were identi-
fied to add conceptual and contextual richness.
At times, the terms medication reconciliation and 
MR were used interchangeably or loosely in studies 
and reports, for thoroughness medication reconciliation 
as well as MR review articles were screened for further 
relevant studies.5 8 11–14 24 31 32 Backward and forward 
reference tracking of included articles was performed 
and sibling papers identified. Multiple papers or reports 
could be related to the same original study and reported 
in conference abstracts, full research reports, evalua-
tion reports, and trial protocols which often outline the 
underlying assumptions of how the programme under 
investigation is supposed to work.
Two members of the research team (KL, MJT) 
screened titles and abstracts for inclusion for full- 
text review. All three authors then read a proportion 
of full- texts, with a random overlap between each, 
which ensured 15% of full- texts were screened by 
all researchers. Any discrepancies in screening were 
resolved through regular discussion. In line with 
realist approaches to data collection any publication or 
document with potential to inform the generation of 
programme theories was considered, this included poli-
cies and procedures of established MR programmes. 
A conventional quality appraisal of studies was not 
performed but all documents were assessed for their 
relevance, trustworthiness and rigour. An assess-
ment of rigour was made by examining whether the 
methods used to generate data were appropriate to 
answer the research questions, were employed with 
fidelity and consistency and could credibly produce 
presented results. Trustworthiness of data was estab-
lished by assessing whether they had been empirically 
obtained and cross- examining outcomes of similar 
studies. Documents were regarded as relevant if they 
were deemed to contribute to the development of 
programme theory or disputed it, with relevance at 
times shifting depending on the developmental phase 
of theory. For documents which seemed highly relevant 
but lacked adequate detail, authors were contacted to 
obtain clarification and additional detail to support 
judgements of trustworthiness and rigour.29
Data analysis
Based on the research questions framed via CIMO, liter-
ature and factors considered in the initial programme 
theory data were extracted from the finally included 
articles, as described in table 1, and considered in 
conjunction with extractions of texts from included 
documents as well as interpretive and reflective notes 
researchers kept on all included documents.27 28 33 All 
data were managed using Microsoft Excel.
Outcomes were categorised into proximal and distal, 
contexts were themed into relevant subcategories and 
mechanisms initially inferred, before refinement of both 
during the synthesis.
Data synthesis and refining programme theory
Causal links, contexts, mechanisms and outcomes were 
then configured iteratively into CMO configurations 
(CMOCs) to refine the programme theory through 
regular discussions by the research team. Working 
backwards from outcomes started the generation of 
CMOCs, followed by interpretation of extracted data 
and author notes in relation to contexts and/or mech-
anisms. Contexts were examined for significance to 
each of the three stages and synthesised after ascer-
taining which outcomes they linked to. Some mecha-
nisms were inferred to start with, as they often were 
Table 1 Template for data extraction
Date extracted from articles included in review
Study type Study type (eg, cohort, RCT)
Participants Patient characteristics, patient- specific inclusion criteria, 
healthcare professionals and their characteristics
Intervention Timing, location, funding, medication review model and 
activities, communication, follow- up, reporting, referrals
Comparator Characteristics of comparator groups if present
Outcomes All outcome measures (process, patient- focused)
Context Individuals, interpersonal relations, institutional settings, 
infrastructure33
Mechanism Qualitative data, theory- based discussions
RCT, randomised controlled trial.
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not articulated clearly or remained hidden until rele-
vant data from all included documents had been exam-
ined. In addition, the relationships between contexts, 
mechanisms and outcomes were established within a 
specific and across all documents. Once a COMC was 
established, all documents were iteratively scrutinised 
for confirmation or disconfirmation. This process 
identified the presence and an absence of mechanisms 
as triggers for outcomes and CMOCs were formulated 
in positive and negative terms.
CMOCs were then examined for demi- regularities 
and abstracted to establish mid- range theories. An 
additional literature search for more general studies 
and documents on MR as well as substantive theory 
was performed to adjudicate and confirm mechanisms 
and the final programme theory.
RESULTS
Sixty- six documents were included, as described in 
the flow chart for their identification and selection in 
figure 1 and listed in online supplemental appendix 3.
Of the 33 primary studies which were reported 
in conference abstracts, trial protocols, journal arti-
cles and evaluation reports, 13 were conducted 
in the UK,20 23 34–44 10 in the USA,18 19 45–52 6 in 
Australia,17 22 53–56 3 in the Netherlands57–59 and 1 in 
Canada.21 Multiple papers or reports could be related 
to the same original study. Findings were reported for 
16 distinct studies of MR performed by pharmacists 
in community pharmacies18–21 34–44 50 (described in 
22 articles), 15 involved home visits17 22 23 46 47 49 51–59 
(described in 32 articles) and 2 in- clinic review.45 48 
Outcome measures are described in table 2.
Fourteen studies reported patient- focused outcomes, 
for example, readmission rates, visits to emergency 
departments rather than the identification or rate 
of resolving MRPs. Seven of those showed positive 
outcomes or trends in reducing hospital readmissions 
or other healthcare utilisation,17–20 45 46 60 four showed 
no differences between intervention and control 
groups21 35 47 48 and three reported increases in hospital 
admissions or other healthcare utilisation for the inter-
vention group.22 23 57 61
Contexts which were identified as potentially influ-
encing outcomes are described in table 3.
Many studies provided limited detail on the inter-
vention. When it was based on an existing MR 
programme, relevant policies and procedures were 
consulted for further guidance and detail, for example, 
for Medication Utilisation Reviews (MUR) in the 
UK, MedsCheck in Ontario and the Home Medicine 
Review (HMR) programme in Australia.62–64
Only two aspects of the intervention seemed to 
consistently trigger mechanisms which facilitated 
favourable outcomes, these were the degrees of 
active problem solving by the pharmacist and mode 
and degree of communication with other healthcare 
providers. Other aspects, for example, timing of the 
MR, credentialing or specific training received by 
pharmacists, seemed to be of little relevance.
Numerous mechanisms were identified as causal 
processes generating outcomes when activated within 
the various contexts, as listed in table 4.
Finally, CMOCs, which were constructed in positive 
and negative terms, describing outcomes when mecha-
nisms were present in a particular context versus their 
absence, are detailed in table 5.
The contribution of the individual CMOCs to the 
overall programme theory is detailed below, separated 
into the steps of an MR as outlined previously.
Step 1: what makes an MR happen?
The first step to the success of any intervention or 
programme is the engagement of the intended partic-
ipants, in this case patients (and their carers), phar-
macists, doctors and other healthcare professionals 
(HCPs). Information on demi- regularities explaining 
which contexts and mechanisms are likely to be in 
place for an MR to happen in the first place was easily 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses flow chart. CINAHL, Cumulative Index of Nursing and Allied 
Health Literature; IPA, International Pharmaceutical Abstracts.
Table 2 Outcome measures of studies
Outcomes
Proximal Process outcomes Interest by patients, patient recruitment/participation (rates), attrition rate after consent, referral rates (by in- hospital 
healthcare professional, doctors), uptake of medication reviews by pharmacists.
Identification of issues Identification of medication- related problems, adherence issues, supply, guideline recommended treatment, patient 
understanding, healthcare needs.
Resolving issues Reported differences of medication- related problems before and after medication reviews.
Distal Hospital readmissions Rate of readmissions.
Healthcare utilisation Emergency department visits, visits to general practitioners.
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obtainable. The following CMOCs relate to ‘what 
makes an MR happen’:
For patients:
Patient recruitment
Patients were generally amenable to considering 
an MR after leaving hospital, in most studies 
60%–70% of those approached in hospital agreed 
to participate, when approached by designated 
personnel.17–19 53 65 66A specific role for recruitment 
was more commonly assigned in hospitals and contin-
gent on the study design gave recruiters a mandate, 
encouraging them to take responsibility. Recruitment 
in community pharmacies was less successful when 
added on to other roles.37 42 Patients consented to 
MR when recruited by HCPs they knew, trusting 
Table 3 Contexts influencing the MR process and outcomes
Context identified from the literature as having potential to influence participation
Context Description
Broadly applicable to 
medication review
Awareness and knowledge of MR 
programmes and referral pathways 
by HCPs
Policies, care models and practices promoting the existence of pharmacist- conducted MR 
programmes determine HCPs’ awareness of the programme and knowledge of how and 
who to refer for a medication review (MR).42 49 71 79 85
Referral pathways were established when existing MR programmes are leveraged or 
extended for MR after discharge18 19 50 51 54 65 76 and/or a triaging system is in place.53 57
Patients’ experience and attitudes 
to pharmacists’ clinical role
Patients have varying experiences of pharmacists exercising their clinical role.36 37 74 77
System and organisational 
structures support MR and facilitate 
role integration
When postdischarge MR programmes were introduced de novo pharmacists only slowly 
integrated them into their practice or business.42 86
Postdischarge MR were implemented as variations of existing programmes, for example, 
Comprehensive Medication Review, Medication Therapy Management in the USA or Home 
Medicines Review in Australia.18 19 21 53 60 78 85 87
Location of MR appointment Most MR were performed in a community pharmacy (CP).18–21 35–41 50 71 86
Several studies where MR was performed in a CP screened out patients who could not 
access the CP.38–41 50 72 74
Patients were visited at home.17 22 23 46 47 49 51–53 57–59 66
MR was performed in a physician’s practice.45 48
Specific to 
postdischarge MR
Location and timing of patient 
recruitment for participation
Patients are approached and recruited to an MR programme while in hospital and 
preparing for discharge.17–20 22 35 41 43 49 59 66 78 79 86 88
Patients receive information about MR while in hospital and are recruited before or when 
they are visiting their CP or before they visit their doctor.40 48 89
Planning and recruitment for MR occurs at a distance from the professional providing MR, 
who is not aware that a patient left hospital.34 38 39 42–44 72
Postdischarge environment, being 
back home
Contact and engagement with patients was difficult to establish once they returned 
home.18–20 41 50 75
Patients were asked to organise their appointment once they returned home.20 37 40 41 43
Patients declined to attend an MR appointment.18–20 35 40 41 50 72 74 75
Contexts identified from the literature as having potential to influence MR process and outcomes
Broadly applicable to 
MR
Information available to pharmacist 
before and during the MR
The pharmacist has access to comprehensive clinical information provided by the 
hospital17 19 and/or a referring primary care provider (eg, doctor)53 60 65 and/or access to an 
electronic health record.18 45 47 48 51 52
Pharmacist has only access to discharge medication list and/or 
summary.20 23 35 37 38 43 44 49 57 58 72
Regulations, standards and funding 
models guiding MR
These determine the extent and expectations of pharmacists’ involvement and scope of 
practice.
MR is expected to be mainly an assessment of MRP, which the pharmacist documents and/
or communicates to other HCPs (eg, the patient’s doctor, community pharmacy).23 57 59
Pharmacist addresses and resolves issues with patient.17–19
Pharmacist identifies and resolves MRPs (eg, dose adjustments) or follows up with other 




collaboration, coordination and 
networks
A network of HCPs coordinates the MR, for example, scheduling of an appointment 
is not left to the patient, appointments are made, doctors are prompted to 
refer, records are shared. This could be through a hospital pharmacist, care- 
navigator (primary care), discharge coordinator (in hospital), GP, community 
pharmacist.17–19 45 46 48 53 55 56 59 60 65 67 87 90
Pharmacists who are tasked to perform MR are informed that patients have been 
discharged.18–20 23 35 46 47 49 50 57–59 86
Pharmacists who are tasked to perform MR are not informed that patients have been 
discharged.39 42 44 71
GP, general practitioner; HCP, healthcare professional; MR, medication reviews; MRP, problem.
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their recommendation.17 53 65 However, reliance on 
referrals by doctors significantly reduced the reach 
of potential patients compared with hospital or 
community pharmacy initiated MR processes, unless 
the referral process was highly coordinated and 
supported, linking to CMOC 7.53 65–67 A combination 
of starting recruitment in hospital and follow- up by 
those involved in the actual MR process seemed to 
maximise patient engagement.18 53 65 These findings 
are abstracted into the following CMOCs:
CMOCs 1: when patients are offered an MR in a 
healthcare environment they are likely to consent 
because they trust the HCP recommending the MR.
When recruitment of patients to an MR is supported 
by an organisation, for example in hospital, recruit-
ment rates increase because ‘recruiters’ have a mandate 
and take responsibility for identifying and consenting 
patients.
Patient experience
Particularly during the early implementation of MR 
programmes, patients were unfamiliar with pharma-
cists’ extended and clinical roles and lacked trust in 
pharmacists’ skill.36 68 In addition, patients’ perception 
of little benefit and low positive outcome expectancy 
of an MR are mechanisms reducing patients’ willing-
ness to participate.36 46 53 69 70
CMOC 2: depending on patients’ experience and 
attitudes to pharmacists’ clinical roles, acceptance of 
an MR referral and participation increases if patients 
perceive a benefit from a pharmacist- led MR and/or 
trust the pharmacist’s skill.
For pharmacists and other HCPs:
Healthcare professional awareness
HCPs, in particular pharmacists and doctors, had 
to gain familiarity with MR programmes. Referrals 
to and/or uptake of MR increased with awareness 
and familiarity because of increasing recognition 
of pharmacists’ clinical and professional role and 
changing perceptions of patients’ benefit from an 
MR.49 51 57 65 66 These mechanisms were confirmed by 
observation or low referral and/or uptake of MR in 
their absence.37–39 53 71–73
CMOC 3: when MR programmes and systems 
have raised HCPs’ awareness and experience, referral 
and uptake increase because they recognise pharma-
cists’ professional role and may perceive a benefit of 
pharmacist- conducted MR for patients.
Role integration
Interlinking with the previous CMOCs additional 
factors influencing pharmacists’ uptake of MR were 
observed. Organisational, policy and procedural 
support had to be in place before pharmacists inte-
grated MR into routine practice. The legitimisation of 
their professional, clinical roles created a mandate to 
perform MR and a positive perception of their profes-
sional standing.18–21 45 48 53 57 Policies and formalised 
MR programmes also signal to pharmacists (and other 
HCPs) that MR is of benefit to patients. When phar-
macists did not accept MR as a professional responsi-
bility and doubted benefits to patients, MR were not 
incorporated into their practice.40 42
CMOC 4: when systems and organisational struc-
tures support MR and facilitate role integration phar-
macists undertake them as routine practice because 
they accept it as part of their professional role and 
Table 4 Mechanisms influencing outcomes
1. Mandate HCPs have a mandate to recruit patients to MR, for example, in hospitals or community pharmacy. 
Pharmacists are given a mandate through regulation and funding and perceive they have a mandate to 
perform MR by patients and other HCPs.
2. Effort required Effort any participant has to make to obtain information to organise or participate in the MR process, for 
example, patients to organise appointments, pharmacists to recruit and organise, doctors to refer.
3. Trust in HCPs Patients trust a referral by a doctor or hospital staff and trust the pharmacist performing MR.
4. Recognition of pharmacists’ clinical and 
professional role
Pharmacists’ competence and skill to perform MR is recognised by pharmacists themselves, other HCPs 
and patients.
5. Perception of benefit from MR by HCPs and 
patients
Patients and HCPs perceptions of benefit from an MR influences their willingness to participate in, refer 
to or conduct an MR.
6. Patient preference Accessibility (6a), acceptability (6b) and convenience (6c) of location and time for MR and who performs 
it (un/familiar pharmacist) (6d).
7. Prioritisation of health and social care needs Patients balance the benefit of MR against other priorities and commitments. MR is not always a priority 
for patients after leaving hospital.
8. Invitation to collaborate Pharmacists personally communicate with or contact doctors about MR, doctors refer patients to 
pharmacists, inviting each other to collaborate.
9. Potential to employ clinical skill Pharmacists are enabled to employ their clinical skills and judgement.
10. Taking responsibility Pharmacists take responsibility for MR outcomes, resolving the issues they can or take responsibility to 
get the ones who can to resolve them.
HCPs take responsibility for recruiting patients to MR.
HCP, healthcare professional; MR, medication reviews.
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perceive a benefit for patients and their own profes-
sional standing.
Location of MR
Despite prescreening, many patients were unable 
to access the location of the MR or relied on carers 
for access to appointments due to poor mobility and 
morbidity, leading to attrition rates of 50% or higher 
after recruitment.18–20 40 41 50 72 74 75 Most programmes 
are inflexible about the location for postdischarge MRs, 
for example, community pharmacies for discharge 
MUR and MedsChecks, homes when leveraging HMR 
programmes. Although not all patients feel comfortable 
attending an MR conducted by a pharmacist they do 
not know or welcome a pharmacist into their home,52 
participation increased when accessing the location 
required little effort.17 23 76 Patients declined participa-
tion when the location of the MR did not meet their 
preferences, which was often the case for community 
pharmacy- based programmes.37 38 40 41 52 74 75
CMOC 5: when the location of the MR is flexible 
patients are more likely to participate because their 
preferences in terms of accessibility, acceptability 
and convenience are met and less effort is required.
Life after hospital
Patients preferences and priorities changed once they 
were home, when they had to reorganise their lives 
and juggle multiple appointments.53 77 Patients partici-
pated (scheduled and attended) an MR when perceived 
benefits outweighed their health and other priorities 
and effort required to attend,37 but frequently that 
balance did not tilt in favour of the MR.18 19 37 50 51 53 78
CMOC 6: when life after hospital has to be reor-
ganised, patients may or may not schedule and 
attend MR appointments because they weigh their 
priorities and effort against perceptions of benefit 
differently.
Steps 2 and 3: what happens and what happens next?
Details on contexts, interventions and mechanisms 
describing what happens during the MR process and 
after the MR was performed were more limited, there-
fore CMOCs outlining these two steps were combined. 
Mechanisms identified for the three CMOCs gener-
ated outcomes along a continuum of activation, the 
stronger mechanisms were activated and the more of 
them were present, the more likely positive outcomes 
were achieved. The following CMOCs relate to the 
MR process: ‘what happens during and after the MR’. 
They frequently acted interdependently, with CMOC 
7 creating favourable conditions for CMOCs 1, 3, 8 
and 9 to develop successfully, and CMOC 8 particu-
larly linked to CMOC 9.
Communication and networks
Community pharmacists who were supposed to under-
take the MR often were not aware patients had left the 
hospital.39 42 44 Independently of the location where 
the MR was undertaken and how patients had been 
engaged, communication within networks and inviting 
pharmacist collaboration increased awareness and 
performance of MRs.18–20 46 48 57–59 79 80 An invitation to 
collaborate, either through a referral from a prescriber 
to the pharmacist or the pharmacist contacting 
prescribers to inform them of their involvement or a 
discussion of MR findings, initiated degrees of shared 
care for a patient and resulted in higher referral53 65–67 
and participation rates17 48 53 65 and achieved positive 
patient outcomes.17 45 48
CMOC 7: because it reduces the effort for those 
involved in the MR process and invites their collabo-
ration, communication and coordination increase the 
likelihood of doctors referring, patients and pharma-
cists scheduling/performing MR and facilitates reduc-
tions in MRPs or readmissions to hospital.
Available information
Information available to pharmacists before and during 
the MR varied between studies, partially dependent 
on regulation and standards, from a hospital discharge 
medication letter to comprehensive referrals including 
relevant clinical information. A referral from a doctor 
constituted an invitation to collaborate, facilitating 
sharing of or requests for information.45 60 65 When 
pharmacists had access to adequate relevant infor-
mation they were enabled to identify most MRPs 
or patient- related problems as well as strategies 
to resolve these, either by action or recommenda-
tion.17–19 45 48 60 65 When only medication information 
was available, pharmacists were hindered in identifying 
clinically relevant issues and identifying or enacting 
appropriate strategies to resolve them.22 23 57 75 77 80
CMOC 8: when pharmacists either receive, or are 
able to easily access, comprehensive and relevant clin-
ical information about patients, MR achieves positive 
outcomes because they are enabled to recognise more 
relevant issues and make recommendations to resolve 
them.
Regulations and standards
While governance of MR programmes influence how 
pharmacists’ can address issues they identify, they 
allow for flexibility and discretion in taking action. 
Pharmacists conducting MR as a holistic clinical 
assessment, at times including social considerations, 
and taking responsibility for outcomes achieved 
significantly higher rates of MRP resolution and 
patient- focused outcomes, for example, reductions 
in readmissions,17–19 46 48 compared with identifying 
MRPs, making recommendations only and leaving 
the solving of problems to someone else without 
follow- up.22 23 57–59 75 80
CMOC 9: better outcomes are achieved when stan-
dards for MR facilitate pharmacists taking respon-
sibility for solving issues identified during the MR, 
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either themselves, in collaboration with the patient, or 
ensuring prescribers resolve any issues they could not 
address.
The predominant absence of the enabling mecha-
nisms of the three CMOCs described above was partic-
ularly observed in the three studies with detrimental 
outcomes, that is, an increase in hospital admissions, 
where a pharmacist, without access to comprehen-
sive information about patients was ‘parachuted in’ 
to undertake an MR and/or sent a medication list and 
additional reporting notes to the doctor without two- 
way communication or formalised follow- up.22 23 57
The final programme theory and connections 
between CMOCs is depicted in figure 2.
DISCUSSION
This realist synthesis of MR performed by pharma-
cists in primary care for people who have left hospital 
provides insight into which contexts have potential to 
influence outcomes and which mechanisms have to be 
activated to achieve positive outcomes for all partici-
pants. Policies, standards, systems and organisational 
structures link to contexts which raise HCPs’ aware-
ness of MR, provide a mandate to recruit and perform 
MR and contribute to role integration for pharmacists. 
They also influence communication, collaboration and 
networks positively.
These more or less generic conditions seem neces-
sary but are insufficient in achieving patient- focused 
outcomes. The following discussion will focus on the 
specific findings with most potential to inform further 
shaping of MR programmes and their implementation.
Patient recruitment and participation
Patients are likely to perceive benefit from an MR 
differently than HCPs, framing it according to their 
needs and preferences will increase their participa-
tion. Deducing from what does not work, increased 
flexibility for the reviewing pharmacist to conduct 
the MR at a location and time which suits patients’ 
preferences and capacity will ensure that those who 
perceive benefit and may benefit are receiving an 
MR. Compelling evidence for a particular time frame 
in which the MR achieves outcome benefit is so far 
lacking, flexibility and meeting preferences in combi-
nation with factors discussed below seem of greater 
importance.
Establishment of trust
Doctors, who in many MR programmes are asked to 
implement pharmacists’ MR recommendations, have 
to perceive a benefit for their patients and trust the 
pharmacist’s professional expertise. As ‘trust pertains 
to relationships with specific others over specific 
matters’81 (italics in original), pharmacists cannot 
assume they are inherently regarded as trustworthy 
and will have to build trust through communication 
and invitations to collaborate.
When implementing MR programmes patients and 
HCPs have to gain trust into the pharmacists’ clinical 
role and skills, and perceive a benefit for an MR. Trust 
in pharmacists can be conferred by a HCP patients 
already trust, with doctors in particular exerting signif-
icant positive social influence over the willingness to 
use a medication management service.82
Communication, coordination, collaboration and 
networks
Communication and coordination between partici-
pating HCPs and patients increases the likelihood of 
participation and positive outcomes because it reduces 
required effort to engage in the MR process. Invitations 
to collaborate between HCPs, for example, doctors 
and pharmacists, enhance collaboration and informa-
tion sharing. Availability of clinical information has 
previously been hypothesised as a factor influencing 
outcomes for an MR in a positive manner.5 The more 
pertinent detail pharmacists have access to the more 
enabled they seemingly are to employ their clinical 
skill and identify MRPs, social issues and other patient 
factors which may contribute to negative outcomes. 
MR programmes have to ensure the quality and rele-
vance of information pharmacists receive before or 
can collect during an MR.
Pharmacists taking responsibility
The manner in which issues are consequently addressed 
influence whether positive outcomes are achieved. 
Lower reductions in MRPs and no changes in health-
care utilisation were observed when pharmacists sent 
reports unsolicited or unannounced to prescribers or 
did not follow- up on their MR findings with patients 
or reports to doctors, confirming that an underlying 
mechanism of initiating or established collabora-
tion comes into play. A patient- focused approach 
and follow- up care has previously been suggested 
to enhance the effectiveness of MR.83 Pharmacists 
resolving issues they can resolve themselves with 
patients, for example, access to medicines, adherence, 
understanding, social support, increases the chances 
of success, and ideally is encouraged by policies and 
systems surrounding MR programmes.
Figure 2 Final programme theory.
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The term ‘review’ unfortunately implies ‘the act 
of considering something in order to make changes 
to it, give an opinion or appraise it’. We hypothesise 
that when pharmacists moved from providing only 
an opinion, assessment or consult to collaborative 
problem solving because they took responsibility for 
the outcome of the postdischarge MR they performed, 
positive outcomes were more likely for people leaving 
hospital.
Strength and limitations
A strength of this synthesis is the inclusion of recent 
research in the area of post- discharge MR.
Many included studies reported outcomes which 
were not necessarily patient- focused and provided 
limited detail on contexts and potential mechanisms.
Issues with patients’ capacity to access the MR point 
to limitations of studies where patients who agreed to 
participate in an MR when approached in hospital but 
could not be contacted after their return home were 
allocated into the usual care or control group. Any 
differences in outcomes might have partly been a func-
tion of patients’ capacity to attend the MR compared 
with those who did not attend, for example, related 
to lesser morbidity and higher mobility, being more 
engaged or self- efficacious in their healthcare, rather 
than attributable solely to the MR.19 20 84 It is also 
plausible that some of these usual care group patients 
were not contactable due to readmission into hospital 
shortly after their previous discharge.75
The intervention, in this case the MR either as a 
process or programme, was often not described in a 
way to assist a realist approach, for example, detail was 
limited20 21 47 or too complex or multifaceted41 57–59 
to understand with certainty which components were 
essential to achieving a positive outcome.
Available data allow confidence in theory of what 
makes an MR happen, particularly in the early phases 
of MR programme implementation, for example, why 
and how stakeholders engage in the MR process or 
not. Due to the above limitations, the programme 
theory relating to tangible outcomes of MR developed 
via this realist synthesis still has to be tested.
CONCLUSIONS
This realist synthesis provides guidance for the future 
development of service models in which pharmacists 
provide MR in primary care for people who have 
left hospital. In order to make it a successful health 
service multiple, interacting elements need to be in 
place. Programmes which offer flexibility in MR loca-
tion and timing, are attuned to patients’ priorities 
and preferences and facilitate coordination and infor-
mation exchange between all participants increase 
uptake and participation. Coordination and collabo-
ration between HCPs and pharmacists taking respon-
sibility for MR outcomes seem to create conditions 
in which the MR leads to patient- relevant outcomes, 
for example, reductions in hospital readmissions. This 
synthesis provides a basis for future (realist) evalua-
tions examining MR in general and for people who 
have left hospital to strengthen and confirm the 
proposed causal explanations.
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